Central diabetes insipidus
disease diseaseOn this page
Also known as CDIdiabetes insipidus cranial typediabetes insipidus neurogenicdiabetes insipidus neurohypophysealneurogenic diabetes insipidus
Summary
Central diabetes insipidus (MONDO:0015790) is a disease and 19 clinical trials. Top therapeutic interventions include desmopressin, vancomycin, and midomafetamine. A subtype of pituitary deficiency — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 17
- Clinical trials: 19
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 4 | Europe | Validated |
Signs & symptoms
Clinical features (HPO)
17 HPO clinical features (Orphanet curated; top 17 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0000017 | Nocturia | Very frequent (80-99%) |
| HP:0000873 | Diabetes insipidus | Very frequent (80-99%) |
| HP:0001508 | Failure to thrive | Very frequent (80-99%) |
| HP:0001824 | Weight loss | Very frequent (80-99%) |
| HP:0001944 | Dehydration | Very frequent (80-99%) |
| HP:0001959 | Polydipsia | Very frequent (80-99%) |
| HP:0002039 | Anorexia | Very frequent (80-99%) |
| HP:0000716 | Depression | Frequent (30-79%) |
| HP:0000739 | Anxiety | Frequent (30-79%) |
| HP:0001254 | Lethargy | Frequent (30-79%) |
| HP:0001262 | Excessive daytime somnolence | Frequent (30-79%) |
| HP:0001945 | Fever | Frequent (30-79%) |
| HP:0002315 | Headache | Frequent (30-79%) |
| HP:0001250 | Seizure | Occasional (5-29%) |
| HP:0002014 | Diarrhea | Occasional (5-29%) |
| HP:0002017 | Nausea and vomiting | Occasional (5-29%) |
| HP:0002902 | Hyponatremia | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | central diabetes insipidus |
| Mondo ID | MONDO:0015790 |
| Orphanet | 178029 |
| DOID | DOID:0081055 |
| ICD-11 | 1009553897 |
| UMLS | C0687720 |
| MedGen | 146919 |
| GARD | 0006015 |
| MedDRA | 10068587 |
| Is cancer (heuristic) | no |
Also known as: CDI · diabetes insipidus cranial type · diabetes insipidus neurogenic · diabetes insipidus neurohypophyseal · neurogenic diabetes insipidus
Data availability: 1 HPO phenotype · 8 cell lines.
Disease family
An umbrella term covering 2 Mondo subtypes.
Classification path: disease › human disease › disease by body system or component › endocrine system disorder › pituitary deficiency › central diabetes insipidus
Related subtypes (4): pituitary deficiency due to Rathke’s pouch cysts, pituitary deficiency due to empty sella turcica syndrome, non-acquired pituitary hormone deficiency, acquired pituitary hormone deficiency
Subtypes (2): neurohypophyseal diabetes insipidus, acquired central diabetes insipidus
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 19.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 8 |
| PHASE2 | 6 |
| PHASE4 | 3 |
| PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04241744 | PHASE4 | WITHDRAWN | Prospective Trial of Oral Vancomycin Therapy vs. Placebo for Prevention of CDI |
| NCT04897802 | PHASE4 | COMPLETED | Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) |
| NCT04902235 | PHASE4 | COMPLETED | Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study) |
| NCT06237452 | PHASE3 | RECRUITING | VE303 for Prevention of Recurrent Clostridioides Difficile Infection |
| NCT01280188 | PHASE3 | COMPLETED | A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI). |
| NCT06036004 | PHASE2 | RECRUITING | Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus |
| NCT06808516 | PHASE2 | RECRUITING | Effects of Intranasal Oxytocin on Sexual Well-Being in Patients With Arginine Vasopressin Deficiency and Healthy Controls |
| NCT03462459 | PHASE2 | COMPLETED | Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection |
| NCT03497806 | PHASE2 | COMPLETED | Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection |
| NCT03621657 | PHASE2 | COMPLETED | The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation |
| NCT03788434 | PHASE2 | COMPLETED | Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection |
| NCT06533800 | Not specified | NOT_YET_RECRUITING | Evaluation of Gut Microbiota and Its Associated Resistome in FMT Donors and Recipients Due to Recurrent Clostridiodes Difficile Infection |
| NCT06604975 | Not specified | NOT_YET_RECRUITING | Arginin-stimulated Copeptin in Polyuria-polydipsia Syndrome in Children |
| NCT06789705 | Not specified | RECRUITING | Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls |
| NCT03474601 | Not specified | UNKNOWN | Seoul National University Pituitary Disease Cohort Study |
| NCT04100603 | Not specified | WITHDRAWN | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Clostridoides Difficile Infection |
| NCT05319301 | Not specified | COMPLETED | Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study) |
| NCT05338125 | Not specified | TERMINATED | Electrophysiology of the Human Pituitary Gland |
| NCT05508607 | Not specified | COMPLETED | Precision Antimicrobial STewardship for Clostridioides DIfficile Prevention |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DESMOPRESSIN | 4 | 1 |
| VANCOMYCIN | 4 | 1 |
| MIDOMAFETAMINE | 3 | 1 |
Related Atlas pages
- Drugs: Desmopressin, Vancomycin, Midomafetamine